Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771264 | 1.00 | CYP2D6 (0.49) | CYP2D6GPR119MMP13MMP1MMP9 | |
| SCHEMBL15472723 | 1.00 | CYP2D6 (0.49) | CYP2D6GPR119MMP13MMP1MMP9 | |
| SCHEMBL222877 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13CYP1A2KMT2A | |
| SCHEMBL221063 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13CYP1A2KMT2A | |
| SCHEMBL221064 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13CYP1A2KMT2A | |
| SCHEMBL19001727 | 0.91 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2AMEN1 | |
| SCHEMBL5447212 | 0.91 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2AMEN1 | |
| SCHEMBL2298971 | 0.88 | CYP2D6 (0.49) | CYP2D6GPR119MMP13MMP1MMP9 | |
| SCHEMBL3127065 | 0.87 | ALDH1A1 (0.52) | GPR119MMP13MMP1MMP9KMT2A | |
| SCHEMBL184777 | 0.86 | CYP2D6 (0.60) | CYP2D6GPR119MMP13KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025237891-A1 | QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-11-20 | — | — | WO | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230087825-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220348556-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-9926299-B2 | Inhibitors of bruton's tyrosine kinase | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087825-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CYP2D6 4549/4885GPR119 3792/4885MMP13 3200/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | CYP2D6 3313/4885GPR119 4238/4885MMP13 2128/4885 |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | SRR, SRRM2, CRBN | CYP2D6 2032/4885GPR119 2508/4885MMP13 1665/4885 |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CYP2D6 604/4885GPR119 2982/4885MMP13 2742/4885 |
| US-20220348556-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | CYP2D6 3313/4885GPR119 4238/4885MMP13 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.